COVID-19
  • CIDRAP Report Details COVID-19 Drug Shortages and Solutions

    The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota has been investigating the vulnerability of the U.S. drug supply chain to shortages of drugs and their active pharmaceutical ingredients, and especially those made in other countries, principally China and India. The emergence of the COVID-19 pandemic in early 2020 has exposed many of these vulnerabilities, as was detailed by David J. Margraf, PharmD, MS, on AANA’s Impact of Drug Shortages During the COVID-19 Pandemic webinar.

    In their recent report, CIDRAP authors offer nine specific recommendations that involve a more coordinated national policy framework to track, identify, mitigate, and prevent drug shortages using a transparent database of drug supply chains. Titled “Part 6: Ensuring a Resilient US Prescription Drug Supply,” the report points out that 29 (72.5%) of the 40 critical drugs for COVID-19 patients are experiencing shortages, according to the American Society of Health-System Pharmacists (ASHP). When these drugs are not available, healthcare providers have to consider rationing existing drug supplies, if any, finding therapeutic substitutes, or even having the patient go without treatment.

    Learn more and read the CIDRAP report and recommendations.